Last night on Health Check with Samuel Adeyemi
White House Pulls Heidi Overton's FDA Nomination on the Eve of a Senate Committee Vote
Facing doubts from Chairman Bill Cassidy and critics in the MAHA movement, the administration steps back and will look for a new nominee to lead the agency.
Filed November 17, 2026 · 📍 White House, DC 20500
Were you there? Share your story
Key points
- The White House withdrew Dr. Heidi Overton's FDA nomination Tuesday, citing a lack of Senate support.
- She was set for a HELP Committee vote Wednesday, where Republicans hold a one-seat edge.
- Chairman Bill Cassidy questioned her management experience and her role in a separate-MMR-shot order.
- Acting Commissioner Kyle Diamantas keeps running the FDA until a new nominee is confirmed.
The White House has withdrawn Dr. Heidi Overton's nomination to lead the Food and Drug Administration, pulling the pick on Tuesday night rather than send her into a committee vote she was unlikely to win. A senior administration official told Axios that Overton lacked the support on Capitol Hill to move forward, and a White House official confirmed the decision to several outlets the same evening [1][2].
The timing was not an accident. Overton had been scheduled to face a vote Wednesday morning in the Senate Health, Education, Labor and Pensions Committee, where Republicans hold just a one-seat edge, and it had become increasingly clear she did not have the votes to clear it [3][4]. With one Republican defection enough to sink her in committee, the administration chose to step back and regroup.
Who Overton Is and Why She Ran Into Trouble
Overton is a preventive medicine physician who most recently served as a deputy director of the White House Domestic Policy Council. She first came to the White House as a fellow on that council during the COVID-19 pandemic in President Trump's first term, later finished a doctorate in clinical investigation at the Johns Hopkins Bloomberg School of Public Health, and served as chief policy officer at the America First Policy Institute before returning to government [5][6].
Her trouble came from two directions at once. On one side, HELP Committee Chairman Bill Cassidy, the Louisiana Republican who is himself a physician, said he had strong concerns about her nomination, pointing to her limited experience running a large organization [3]. Cassidy also took aim at her role in an August executive order encouraging separate measles, mumps and rubella shots, describing her support for splitting up combination vaccines as almost disqualifying [3][6]. Other Republican senators told reporters this week that they were still undecided [3].
On the other side, some of the loudest voices in the Make America Healthy Again movement were not in her corner either. Calley Means, a former Trump administration aide, publicly accused Overton of undermining Health Secretary Robert F. Kennedy Jr.'s agenda [3]. That left the nominee squeezed between senators who thought she went too far on vaccines and activists who feared she would not go far enough.
What the Hearing Showed
At her September 24 confirmation hearing, Overton tried to thread that needle. She told senators that every vaccine now on the U.S. market is safe and effective according to the FDA, and she said plainly that the combined MMR shot is not lethal [6]. Asked about the separate-shot order, she said the president wanted to give parents an additional option, not take the MMR vaccine away [6]. She also acknowledged a practical problem: no single-disease measles, mumps or rubella vaccines are currently sold in the United States [6].
Semafor later reported that, as a Domestic Policy Council aide, Overton helped edit and craft the scientific justification used to support January's reduction of the CDC's routine childhood recommendations from 17 vaccines to 11 [5]. For Cassidy and other senators focused on childhood immunization, that record became central.
Senators also pressed her on mifepristone, the abortion drug whose safety review is a top concern for pro-life Americans. Overton largely avoided stating a position at the hearing [6]. That question will not go away. Whoever is nominated next will be asked the same thing, and pro-life voters will be watching the answer closely.
Who Runs the FDA Now
For now, nothing changes day to day at the agency. The FDA has been run by acting Commissioner Kyle Diamantas since Marty Makary resigned in May, according to reports on the withdrawal [2][3]. The White House has not said who it will nominate in Overton's place [2].
Why It Matters
The FDA approves the medicines in your cabinet, polices the safety of much of the food on your table and sets the rules for vaccines, vaping products and drugs like mifepristone. A permanent, Senate-confirmed leader carries more weight with drug makers, with Congress and with the public than an acting chief can.
There is a fair case that the White House made the right call. Forcing a vote that was likely to fail would have handed critics an easy headline and burned weeks of the Senate calendar. Pulling the nomination quietly, the night before the committee met, keeps the focus where it belongs: finding a nominee who can earn a committee majority while carrying out the president's promise to put families, parents and honest science first.
The episode also shows that the coalition behind health reform is not one voice. Senators who trust the existing vaccine system, activists who want it reexamined, and pro-life voters who want a hard look at abortion drugs all have a stake in the FDA. The next nominee will need to speak to all three.
What Comes Next
The administration will have to pick a new candidate and start the confirmation process over, beginning with paperwork, Senate meetings and a new HELP Committee hearing [1][2]. Until then, Diamantas remains in charge [2]. The calendar matters, too: a new Congress takes office in January, and every week without a nominee is a week the agency's biggest decisions wait on an acting chief.
Sources
What worries you most about health care?
- Cost
- Getting an appointment
- Quality of care
- Government getting more involved
Were you there?
If you were at the scene, or this story touched your life, tell us what you saw and what it was like.



Discussion 0
Sign in or create a free account to join the discussion.
No comments yet. Start the discussion.